OBJECTIVES:
The national government is repositioning the Community Pharmacies (CP) in the national health service, through definition of different: mix of services, relation with other health care actors, and range of objectives to achieve. Considering the contextual factors, the paper aims at analyzing the managerial implication for CP. For this purpose the CPs' director strategic attitude and the structure of the information system are investigated. METHODS: The paper is based on literature review and on a survey conducted among a national sample of 695 community pharmacies (CP). Data were collected through a questionnaire organized in both open questions and closed questions (Likert scale 1-7). Data were analyzed according to descriptive statistics to support the qualitative study approach. The SPSS program was used. RESULTS: Respondents have limited awareness of the different actions that the national and regional contexts implement regard to the CP. Although, the mix of services provided is heterogeneous and not widely consistent with the aims of the government reform (2009 law decree), there is a positive willingness to extent the professional role. Increasing the mix of services provided is perceived a strategic action (mϭ5,09), services are delivered even if the contribution to the CP's revenues is very low (mϭ2,62). The information system allows the monitoring of the overall financial results (mϭ5,33), while its relevance decreases with regard to the CP's cost structure (mϭ4,5) and to the specific service/business area's contribution to the general results (mϭ4,18).
CONCLUSIONS:
The study suggests that CP's directors haven't developed an effective strategic orientation yet. The actual information system is not able to support them to manage the changes. As long as CPs' director develop a strategic orientation, they could act as agent of change.
PHP110 GAINING REIMBURSEMENT OF ORPHAN PRODUCTS IN EUROPE: CHALLENGES DUE TO WIDE VARIATIONS IN EVIDENCE REQUIREMENTS AND PROCESSES
Heron L 1 , Laurenson S 1 , Costello J 1 , Anderl C 2 , Knospe J 2 1 Adelphi Values, Bollington, Cheshire, UK, 2 Santen GmbH, Germering, Germany OBJECTIVES: Understand country-specific evidence requirements for the national reimbursement of orphan products (disease prevalence: Ͻ5/10,000) in the UK, France, Spain, Italy and Germany. METHODS: Qualitative research identified guidelines for reimbursement submission from each national reimbursement body. 1-5 orphan product appraisals per country were also reviewed to gain insight into the application of guidelines. Findings are based only on review of the guidelines and selected appraisals. RESULTS: The markets studied do not have reimbursement processes specifically for orphan products, however special considerations exist. For example, while direct comparator trials are the preferred sources of clinical evidence for non-orphan products, in certain instances reimbursement of orphan products has been granted based on placebo-controlled trials accompanied by indirect treatment comparisons. In England, exemptions are made only for orphan products which extend survival in patients with short life expectancies. In Scotland, 62% of decisions on orphan indications have been negative, mostly due to a lack of robust economic evidence. In Italy, access to orphan products is encouraged and 94% of those launched are reimbursed: a lower benefit-risk ratio and evidence outside randomized controlled trials is accepted for orphan products. In France, orphan products benefit from fast-track procedures; however no special evidence considerations are acknowledged. Under AM-NutzenV in Germany, the medical benefit of orphan products is considered confirmed through the marketing authorisation; thus orphan submissions require a limited submission document. Whilst no national practices for orphan products exist in Spain, some regions implement risk-sharing agreements. CONCLUSIONS: Whilst reimbursement bodies recognize data limitations and provide special considerations for orphan products, processes are not explicit and requirements vary, leading to uncertainty in the reimbursement evidence requirements. It is therefore important to engage with appropriate reimbursement bodies to fully determine their specific requirements and modify one's submission to demonstrate an orphan product's ability to meet payers' needs.
PHP111 FACTORS PREDICTING REIMBURSEMENT DECISIONS ON ORPHAN DRUGS IN EIGHT COUNTRIES
Kanters T, Redekop W, Hakkaart L Erasmus University Rotterdam, Rotterdam, The Netherlands OBJECTIVES: The number of orphan drugs has increased vastly over the last years. However, the reimbursement of orphan drugs remains a black box. The objective of this study was to examine how much reimbursement decisions are influenced by disease-related and financial aspects of orphan drugs. METHODS: We examined publicly available reimbursement decisions for all 11 orphan drugs listed on the Dutch policy rule in eight countries (Australia, Belgium, Canada, England, Ireland, New Zealand, Scotland, and Wales). We examined whether the proportion of positive reimbursement decisions (based on the originally submitted price) depended on number of eligible patients, treatment costs, budget impact or timing of application. Information on these factors were based on the Dutch situation. RESULTS: For these 11 orphan drugs, 45 reimbursement decisions were publicly available, of which 12 decisions were positive. In addition, three decisions were positive for only a subgroup of an indication (infantile Pompe disease) and negative for all other patients (late-onset Pompe disease). Furthermore, in two cases the orphan drug was not eligible for reimbursement at the originally submitted price. One decision was deferred to allow additional data collection. The proportion of positive reimbursement decisions decreased as treatment cost per patient increased. A similar relationship was observed between total budget impact and proportion of positive reimbursement decisions. The number of eligible patients did not influence the proportion of positive reimbursement decisions. The proportion of positive decisions was lower for orphan drugs that were added to the policy rule at a later time. CONCLUSIONS: The proportion of positive reimbursement decisions is lower for drugs with higher treatment costs or budget impact. Future studies should be conducted with country-specific explanatory factors. Furthermore, future research should not only examine the outcomes of reimbursement decisions, but also study the entire reimbursement process to identify areas of improvement. 
PHP112 ESTIMATING THE PROBABILITY OF A FAVORABLE ASSESSMENT OF CLINICAL BENEFITS FOR A NEW DRUG IN GERMANY USING AN MCDA APPROACH

OBJECTIVES:
To develop a quantitative process to estimate the probability of a favorable assessment of additional clinical benefit for a new drug for a chronic non-life threatening disease in Germany METHODS: A multi-criteria decision process was use that included: selection of 7 German decision makers; pre-workshop questionnaires to identify the most important attributes for the decision and their relative importance; a workshop to develop levels for the most important attributes, map each attribute level to a value function and identify marginal drug profiles (drugs just demonstrating 'additional clinical benefit'); post-workshop estimation of weighted scores for each marginal product based on the estimated values and relative importance of their attribute levels and a logistic regression model to estimate the probability of an 'additional clinical benefit' decision as a function of the weighted scores; post-workshop questionnaire to validate the logistic regression model using participant ratings for some hypothetical products. RESULTS: The most important attributes identified for a determination of 'additional clinical benefit' and their relative importance weights (%) were: robustness of clinical evidence (29%); incremental efficacy (19%); unmet need (12%); incremental impact on QOL (10%); availability of alternative treatments (9%); safety of new drug (9%); burden of disease (5%); availability of other country evaluations (4%); budget impact (3%). The attribute levels and relative value for a positive decision (0-1) for the most important attribute, robustness of clinical evidence, were: 'endpoints and/or comparators not relevant to patients' (0); 'clinical endpoints relevant but comparators not relevant needing indirect comparisons' (0.764); and 'all clinical endpoints and comparators relevant for patients and payers (1)'. The estimates of the probability of an 'additional clinical benefit' for the hypothetical products using the logistic regression model had 71% positive predictive value and 85% negative predictive value when compared to participant decisions for these hypothetical products. CONCLUSIONS: An MCDA process can provide both a qualitative understanding and quantitative estimates of the relative importance, attribute levels, and value scales of different product attributes that influence a decision of 'additional clinical benefit' in Germany.
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